The Hippo signal transduction pathway in soft tissue sarcomas

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1856, Issue 1, 2015, Pages 121-129

  Mohamed, Abdalla D ^a   Tremblay, Annie M ^b,c,d   Murray, Graeme I ^a   Wackerhage, Henning ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Harvard University   (United States)

^d HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Fusion genes; Hippo pathway; Rhabdomyosarcoma; Sarcoma; TAZ; YAP

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DYSTROPHIN; G PROTEIN COUPLED RECEPTOR; HIPPO PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; K RAS PROTEIN; LYSOPHOSPHATIDIC ACID; MERLIN; MEVALONIC ACID; MOB1 PROTEIN; MUTANT PROTEIN; PEPTIDE DERIVATIVE; PROTEIN KINASE; SPHINGOSINE 1 PHOSPHATE; TRANSCRIPTION FACTOR YAP1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VERTEPORFIN; HIPPO PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

CANCER CLASSIFICATION; CANCER INHIBITION; CHONDROSARCOMA; CROSS LINKING; CTNNB1 GENE; EMBRYONAL RHABDOMYOSARCOMA; EPIGENETICS; EPITHELIOID HAEMANGIOENDOTHELIOMA; EXTRASKELETAL OSTEOSARCOMA; FBXW7 GENE; FUSION GENE; GENE; GENE DOSAGE; GENE FREQUENCY; GENE TARGETING; GENETICS; GENOMICS; HEMANGIOENDOTHELIOMA; HETEROZYGOSITY; HIPPO GENE; HUMAN; LATS1 GENE; MOB1 GENE; NEUROFIBROMATOSIS TYPE 2; NF2 GENE; NONHUMAN; ONCOGENE K RAS; OSTEOSARCOMA; PIK3CA GENE; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SKIN FIBROSARCOMA; SOFT TISSUE SARCOMA; TRANSGENIC MOUSE; TUMOR GENE; UTERUS SARCOMA; WWTR1 CAMTA1 GENE; YAP1 GENE; YAP1 TFE3 GENE; ANIMAL; DISEASE MODEL; METABOLISM; MOUSE; PATHOLOGY; SARCOMA;

MUS MUSCULUS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; PROTEIN-SERINE-THREONINE KINASES; SARCOMA; SIGNAL TRANSDUCTION;

EID: 84934278976     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.05.006     Document Type: Review

References (107)

1. Udan R.S., Kango-Singh M., Nolo R., Tao C., Halder G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat. Cell Biol. 2003, 5:914-920.
2. Harvey K.F., Zhang X., Thomas D.M. The Hippo pathway and human cancer. Nat. Rev. Cancer 2013, 13:246-257.
3. Moroishi T., Hansen C.G., Guan K.L. The emerging roles of YAP and TAZ in cancer, nature reviews. Cancer 2015, 15:73-79.
4. Harvey K., Tapon N. The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat. Rev. Cancer 2007, 7:182-191.
5. Pan D. The hippo signaling pathway in development and cancer. Dev. Cell 2010, 19:491-505.
6. Taylor B.S., Barretina J., Maki R.G., Antonescu C.R., Singer S., Ladanyi M. Advances in sarcoma genomics and new therapeutic targets, nature reviews. Cancer 2011, 11:541-557.
7. Goldblum J.R.F., A.L., Weiss S. Enzinger and Weiss's Soft Tissue Tumors 2014, Elsevier. 6th ed.
8. Anderson J.L., Denny C.T., Tap W.D., Federman N. Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr. Res. 2012, 72:112-121.
9. Fletcher B.S., Bridge J.A., Hogendoorn P.C.D., Mertens F., World Health Organisation Classification of tumours: Tumours of Soft Tissue and Bone 2013, WHO Press. 4th ed.
10. Fletcher C.D. The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification. Histopathology 2014, 64:2-11.
11. Fisher C. Immunohistochemistry in diagnosis of soft tissue tumours. Histopathology 2011, 58:1001-1012.
12. Fisher C. Dataset for Histopathology Reporting of Soft Tissue Sarcomas 2014, T.R.C.o. Pathologists (Ed.).
13. Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., Meyerson M., Gabriel S.B., Lander E.S., Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
14. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
15. Antonescu C.R., Le Loarer F., Mosquera J.M., Sboner A., Zhang L., Chen C.L., Chen H.W., Pathan N., Krausz T., Dickson B.C., Weinreb I., Rubin M.A., Hameed M., Fletcher C.D. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosom. Cancer 2013, 52:775-784.
16. Errani C., Zhang L., Sung Y.S., Hajdu M., Singer S., Maki R.G., Healey J.H., Antonescu C.R. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosom. Cancer 2011, 50:644-653.
17. Helias-Rodzewicz Z., Perot G., Chibon F., Ferreira C., Lagarde P., Terrier P., Coindre J.M., Aurias A. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosom. Cancer 2010, 49:1161-1171.
18. Tremblay A.M., Missiaglia E., Galli G.G., Hettmer S., Urcia R., Carrara M., Judson R.N., Thway K., Nadal G., Selfe J.L., Murray G., Calogero R.A., De Bari C., Zammit P.S., Delorenzi M., Wagers A.J., Shipley J., Wackerhage H., Camargo F.D. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell 2014, 26:273-287.
19. Hallor K.H., Sciot R., Staaf J., Heidenblad M., Rydholm A., Bauer H.C., Astrom K., Domanski H.A., Meis J.M., Kindblom L.G., Panagopoulos I., Mandahl N., Mertens F. Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J. Pathol. 2009, 217:716-727.
20. Gambaro K., Quinn M.C., Wojnarowicz P.M., Arcand S.L., de Ladurantaye M., Barres V., Ripeau J.S., Killary A.M., Davis E.C., Lavoie J., Provencher D.M., Mes-Masson A.M., Chevrette M., Tonin P.N. VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer. Mol. Oncol. 2013, 7:513-530.
21. Parham D.M., Ellison D.A. Rhabdomyosarcomas in adults and children: an update. Arch. Pathol. Lab. Med. 2006, 130:1454-1465.
22. Van Mater D., Ano L., Blum J.M., Webster M.T., Huang W., Williams N., Ma Y., Cardona D.M., Fan C.M., Kirsch D.G. Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway. Cancer Res. 2015, 75:605-614.
23. Liebner D.A. The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma. J. Surg. Oncol. 2015, 111:622-631.
24. Gronchi A., Colombo C., Raut C.P. Surgical management of localized soft tissue tumors. Cancer 2014, 120:2638-2648.
25. Linch M., Miah A.B., Thway K., Judson I.R., Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies, nature reviews. Clin. Oncol. 2014, 11:187-202.
26. D'Angelo S.P., Tap W.D., Schwartz G.K., Carvajal R.D. Sarcoma immunotherapy: past approaches and future directions. Sarcoma 2014, 2014:391967.
27. Radaelli S., Stacchiotti S., Casali P.G., Gronchi A. Emerging therapies for adult soft tissue sarcoma. Expert. Rev. Anticancer. Ther. 2014, 14:689-704.
28. Al-Zaid T., Somaiah N., Lazar A.J. Targeted therapies for sarcomas: new roles for the pathologist. Histopathology 2014, 64:119-133.
29. Forscher C., Mita M., Figlin R. Targeted therapy for sarcomas. Biologics Targets Ther. 2014, 8:91-105.
30. Neuville A., Chibon F., Coindre J.M. Grading of soft tissue sarcomas: from histological to molecular assessment. Pathology 2014, 46:113-120.
31. Edge S.B., D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. AJCC Cancer Staging Manual 2010, Springer. 7th ed.
32. Gateff E. Malignant neoplasms of genetic origin in Drosophila melanogaster. Science 1978, 200:1448-1459.
33. Avruch J., Zhou D., Fitamant J., Bardeesy N., Mou F., Barrufet L.R. Protein kinases of the Hippo pathway: regulation and substrates. Semin. Cell Dev. Biol. 2012, 23:770-784.
34. Oka T., Mazack V., Sudol M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J. Biol. Chem. 2008, 283:27534-27546.
35. Zhao B., Li L., Tumaneng K., Wang C.Y., Guan K.L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 2010, 24:72-85.
36. Lei Q.Y., Zhang H., Zhao B., Zha Z.Y., Bai F., Pei X.H., Zhao S., Xiong Y., Guan K.L. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol. Cell. Biol. 2008, 28:2426-2436.
37. Rosenbluh J., Nijhawan D., Cox A.G., Li X., Neal J.T., Schafer E.J., Zack T.I., Wang X., Tsherniak A., Schinzel A.C., Shao D.D., Schumacher S.E., Weir B.A., Vazquez F., Cowley G.S., Root D.E., Mesirov J.P., Beroukhim R., Kuo C.J., Goessling W., Hahn W.C. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012, 151:1457-1473.
38. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 1994, 9:2145-2152.
39. Sudol M., Bork P., Einbond A., Kastury K., Druck T., Negrini M., Huebner K., Lehman D. Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J. Biol. Chem. 1995, 270:14733-14741.
40. Zhao B., Ye X., Yu J., Li L., Li W., Li S., Yu J., Lin J.D., Wang C.Y., Chinnaiyan A.M., Lai Z.C., Guan K.L. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008, 22:1962-1971.
41. Koontz L.M., Liu-Chittenden Y., Yin F., Zheng Y., Yu J., Huang B., Chen Q., Wu S., Pan D. The Hippo effector yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev. Cell 2013, 25:388-401.
42. Aragon E., Goerner N., Zaromytidou A.I., Xi Q., Escobedo A., Massague J., Macias M.J. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev. 2011, 25:1275-1288.
43. Murakami M., Nakagawa M., Olson E.N., Nakagawa O. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18034-18039.
44. Dupont S., Morsut L., Aragona M., Enzo E., Giulitti S., Cordenonsi M., Zanconato F., Le D.J., Forcato M., Bicciato S., Elvassore N., Piccolo S. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474:179-183.
45. Azzolin L., Zanconato F., Bresolin S., Forcato M., Basso G., Bicciato S., Cordenonsi M., Piccolo S. Role of TAZ as mediator of Wnt signaling. Cell 2012, 151:1443-1456.
46. Azzolin L., Panciera T., Soligo S., Enzo E., Bicciato S., Dupont S., Bresolin S., Frasson C., Basso G., Guzzardo V., Fassina A., Cordenonsi M., Piccolo S. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 2014, 158:157-170.
47. Yu F.X., Zhao B., Panupinthu N., Jewell J.L., Lian I., Wang L.H., Zhao J., Yuan H., Tumaneng K., Li H., Fu X.D., Mills G.B., Guan K.L. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150:780-791.
48. Dong J., Feldmann G., Huang J., Wu S., Zhang N., Comerford S.A., Gayyed M.F., Anders R.A., Maitra A., Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133.
49. Camargo F.D., Gokhale S., Johnnidis J.B., Fu D., Bell G.W., Jaenisch R., Brummelkamp T.R. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 2007, 17:2054-2060.
50. Schlegelmilch K., Mohseni M., Kirak O., Pruszak J., Rodriguez J.R., Zhou D., Kreger B.T., Vasioukhin V., Avruch J., Brummelkamp T.R., Camargo F.D. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011, 144:782-795.
51. Yu T., Bachman J., Lai Z.C. Mutation analysis of large tumor suppressor genes LATS1 and LATS2 supports a tumor suppressor role in human cancer. Protein Cell 2015, 6:6-11.
52. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., Cerami E., Sander C., Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6:l1.
53. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., Antipin Y., Reva B., Goldberg A.P., Sander C., Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404.
54. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., Carter S.L., Stewart C., Mermel C.H., Roberts S.A., Kiezun A., Hammerman P.S., McKenna A., Drier Y., Zou L., Ramos A.H., Pugh T.J., Stransky N., Helman E., Kim J., Sougnez C., Ambrogio L., Nickerson E., Shefler E., Cortes M.L., Auclair D., Saksena G., Voet D., Noble M., DiCara D., Lin P., Lichtenstein L., Heiman D.I., Fennell T., Imielinski M., Hernandez B., Hodis E., Baca S., Dulak A.M., Lohr J., Landau D.A., Wu C.J., Melendez-Zajgla J., Hidalgo-Miranda A., Koren A., McCarroll S.A., Mora J., Lee R.S., Crompton B., Onofrio R., Parkin M., Winckler W., Ardlie K., Gabriel S.B., Roberts C.W., Biegel J.A., Stegmaier K., Bass A.J., Garraway L.A., Meyerson M., Golub T.R., Gordenin D.A., Sunyaev S., Lander E.S., Getz G. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
55. Sima J., Gilbert D.M. Complex correlations: replication timing and mutational landscapes during cancer and genome evolution. Curr. Opin. Genet. Dev. 2014, 25C:93-100.
56. Overholtzer M., Zhang J., Smolen G.A., Muir B., Li W., Sgroi D.C., Deng C.X., Brugge J.S., Haber D.A. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12405-12410.
57. Shao D.D., Xue W., Krall E.B., Bhutkar A., Piccioni F., Wang X., Schinzel A.C., Sood S., Rosenbluh J., Kim J.W., Zwang Y., Roberts T.M., Root D.E., Jacks T., Hahn W.C. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014, 158:171-184.
58. Kapoor A., Yao W., Ying H., Hua S., Liewen A., Wang Q., Zhong Y., Wu C.J., Sadanandam A., Hu B., Chang Q., Chu G.C., Al-Khalil R., Jiang S., Xia H., Fletcher-Sananikone E., Lim C., Horwitz G.I., Viale A., Pettazzoni P., Sanchez N., Wang H., Protopopov A., Zhang J., Heffernan T., Johnson R.L., Chin L., Wang Y.A., Draetta G., DePinho R.A. Yap1 activation enables bypass of oncogenic kras addiction in pancreatic cancer. Cell 2014, 158:185-197.
59. Zhang W., Nandakumar N., Shi Y., Manzano M., Smith A., Graham G., Gupta S., Vietsch E.E., Laughlin S.Z., Wadhwa M., Chetram M., Joshi M., Wang F., Kallakury B., Toretsky J., Wellstein A., Yi C. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci. Signal. 2014, 7:ra42.
60. John M.A.St, Tao W., Fei X., Fukumoto R., Carcangiu M.L., Brownstein D.G., Parlow A.F., McGrath J., Xu T. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat. Genet. 1999, 21:182-186.
61. McClatchey A.I., Saotome I., Mercer K., Crowley D., Gusella J.F., Bronson R.T., Jacks T. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 1998, 12:1121-1133.
62. Nishio M., Hamada K., Kawahara K., Sasaki M., Noguchi F., Chiba S., Mizuno K., Suzuki S.O., Dong Y., Tokuda M., Morikawa T., Hikasa H., Eggenschwiler J., Yabuta N., Nojima H., Nakagawa K., Hata Y., Nishina H., Mimori K., Mori M., Sasaki T., Mak T.W., Nakano T., Itami S., Suzuki A. Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice. J. Clin. Invest. 2012, 122:4505-4518.
63. Hamaratoglu F., Willecke M., Kango-Singh M., Nolo R., Hyun E., Tao C., Jafar-Nejad H., Halder G. The tumour-suppressor genes NF2/merlin and expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol. 2006, 8:27-36.
64. Zhang N., Bai H., David K.K., Dong J., Zheng Y., Cai J., Giovannini M., Liu P., Anders R.A., Pan D. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 2010, 19:27-38.
65. Hergovich A. MOB control: reviewing a conserved family of kinase regulators. Cell. Signal. 2011, 23:1433-1440.
66. Watt K.I., Judson R., Medlow P., Reid K., Kurth T.B., Burniston J.G., Ratkevicius A., De Bari C., Wackerhage H. Yap is a novel regulator of C2C12 myogenesis. Biochem. Biophys. Res. Commun. 2010, 393:619-624.
67. Judson R.N., Tremblay A.M., Knopp P., White R.B., Urcia R., De B.C., Zammit P.S., Camargo F.D., Wackerhage H. The Hippo pathway member Yap plays a key role in influencing fate decisions in muscle satellite cells. J. Cell Sci. 2012, 125:6009-6019.
68. Pallafacchina G., Francois S., Regnault B., Czarny B., Dive V., Cumano A., Montarras D., Buckingham M. An adult tissue-specific stem cell in its niche: a gene profiling analysis of in vivo quiescent and activated muscle satellite cells. Stem Cell Res. 2010, 4:77-91.
69. Chamberlain J.S., Metzger J., Reyes M., Townsend D., Faulkner J.A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 2007, 21:2195-2204.
70. Hosur V., Kavirayani A., Riefler J., Carney L.M., Lyons B., Gott B., Cox G.A., Shultz L.D. Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma. Cancer Genet. 2012, 205:232-241.
71. Flucke U., Vogels R.J., de Saint Aubain Somerhausen N., Creytens D.H., Riedl R.G., van Gorp J.M., Milne A.N., Huysentruyt C.J., Verdijk M.A., van Asseldonk M.M., Suurmeijer A.J., Bras J., Palmedo G., Groenen P.J., Mentzel T. Epithelioid hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases. Diagn. Pathol. 2014, 9:131.
72. Missiaglia E., Williamson D., Chisholm J., Wirapati P., Pierron G., Petel F., Concordet J.P., Thway K., Oberlin O., Pritchard-Jones K., Delattre O., Delorenzi M., Shipley J. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 2012, 30:1670-1677.
73. Shern J.F., Chen L., Chmielecki J., Wei J.S., Patidar R., Rosenberg M., Ambrogio L., Auclair D., Wang J., Song Y.K., Tolman C., Hurd L., Liao H., Zhang S., Bogen D., Brohl A.S., Sindiri S., Catchpoole D., Badgett T., Getz G., Mora J., Anderson J.R., Skapek S.X., Barr F.G., Meyerson M., Hawkins D.S., Khan J. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014, 4:216-231.
74. Mosquera J.M., Sboner A., Zhang L., Kitabayashi N., Chen C.L., Sung Y.S., Wexler L.H., LaQuaglia M.P., Edelman M., Sreekantaiah C., Rubin M.A., Antonescu C.R. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosom. Cancer 2013, 52:538-550.
75. Tanas M.R., Ma S., Jadaan F.O., Ng C.K., Weigelt B., Reis-Filho J.S., Rubin B.P. Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein. Oncogene 2015, (in press).
76. Ciriello G., Miller M.L., Aksoy B.A., Senbabaoglu Y., Schultz N., Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 2013, 45:1127-1133.
77. Barretina J., Taylor B.S., Banerji S., Ramos A.H., Lagos-Quintana M., Decarolis P.L., Shah K., Socci N.D., Weir B.A., Ho A., Chiang D.Y., Reva B., Mermel C.H., Getz G., Antipin Y., Beroukhim R., Major J.E., Hatton C., Nicoletti R., Hanna M., Sharpe T., Fennell T.J., Cibulskis K., Onofrio R.C., Saito T., Shukla N., Lau C., Nelander S., Silver S.J., Sougnez C., Viale A., Winckler W., Maki R.G., Garraway L.A., Lash A., Greulich H., Root D.E., Sellers W.R., Schwartz G.K., Antonescu C.R., Lander E.S., Varmus H.E., Ladanyi M., Sander C., Meyerson M., Singer S. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 2010, 42:715-721.
78. Antonescu C.R., Zhang L., Nielsen G.P., Rosenberg A.E., Dal Cin P., Fletcher C.D. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosom. Cancer 2011, 50:757-764.
79. Jiao S., Wang H., Shi Z., Dong A., Zhang W., Song X., He F., Wang Y., Zhang Z., Wang W., Wang X., Guo T., Li P., Zhao Y., Ji H., Zhang L., Zhou Z. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 2014, 25:166-180.
80. Takahashi Y., Miyoshi Y., Takahata C., Irahara N., Taguchi T., Tamaki Y., Noguchi S. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin. Cancer Res. 2005, 11:1380-1385.
81. Jiang Z., Li X., Hu J., Zhou W., Jiang Y., Li G., Lu D. Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci. Res. 2006, 56:450-458.
82. Seidel C., Schagdarsurengin U., Blumke K., Wurl P., Pfeifer G.P., Hauptmann S., Taubert H., Dammann R. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol. Carcinog. 2007, 46:865-871.
83. Tremblay A.M., Camargo F.D. Hippo signaling in mammalian stem cells. Semin. Cell Dev. Biol. 2012, 23:818-826.
84. Crose L.E., Galindo K.A., Kephart J.G., Chen C., Fitamant J., Bardeesy N., Bentley R.C., Galindo R.L., Ashley Chi J.T., Linardic C.M. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. J. Clin. Invest. 2014, 124:285-296.
85. Williamson D., Missiaglia E., de R.A., Pierron G., Thuille B., Palenzuela G., Thway K., Orbach D., Lae M., Freneaux P., Pritchard-Jones K., Oberlin O., Shipley J., Delattre O. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 2010, 28:2151-2158.
86. Chen X., Stewart E., Shelat A.A., Qu C., Bahrami A., Hatley M., Wu G., Bradley C., McEvoy J., Pappo A., Spunt S., Valentine M.B., Valentine V., Krafcik F., Lang W.H., Wierdl M., Tsurkan L., Tolleman V., Federico S.M., Morton C., Lu C., Ding L., Easton J., Rusch M., Nagahawatte P., Wang J., Parker M., Wei L., Hedlund E., Finkelstein D., Edmonson M., Shurtleff S., Boggs K., Mulder H., Yergeau D., Skapek S., Hawkins D.S., Ramirez N., Potter P.M., Sandoval J.A., Davidoff A.M., Mardis E.R., Wilson R.K., Zhang J., Downing J.R., Dyer M.A., St P. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome, targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013, 24:710-724.
87. Lin L., Sabnis A.J., Chan E., Olivas V., Cade L., Pazarentzos E., Asthana S., Neel D., Yan J.J., Lu X., Pham L., Wang M.M., Karachaliou N., Cao M.G., Manzano J.L., Ramirez J.L., Torres J.M., Buttitta F., Rudin C.M., Collisson E.A., Algazi A., Robinson E., Osman I., Munoz-Couselo E., Cortes J., Frederick D.T., Cooper Z.A., McMahon M., Marchetti A., Rosell R., Flaherty K.T., Wargo J.A., Bivona T.G. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 2015, 47:250-256.
88. Hinson A.R., Jones R., Crose L.E., Belyea B.C., Barr F.G., Linardic C.M. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front. Oncol. 2013, 3:183.
89. Fan R., Kim N.G., Gumbiner B.M. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2569-2574.
90. Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., Cheng J.Q. Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic signaling through phosphorylation of threonine 120. J. Biol. Chem. 2010, 285:3815-3824.
91. Jang S.W., Yang S.J., Srinivasan S., Ye K. Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. J. Biol. Chem. 2007, 282:30836-30844.
92. Collak F.K., Yagiz K., Luthringer D.J., Erkaya B., Cinar B. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1. J. Biol. Chem. 2012, 287:23698-23709.
93. Yeung C.L., Ngo V.N., Grohar P.J., Arnaldez F.I., Asante A., Wan X., Khan J., Hewitt S.M., Khanna C., Staudt L.M., Helman L.J. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene 2013, 32:5429-5438.
94. Liu C.Y., Zha Z.Y., Zhou X., Zhang H., Huang W., Zhao D., Li T., Chan S.W., Lim C.J., Hong W., Zhao S., Xiong Y., Lei Q.Y., Guan K.L. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J. Biol. Chem. 2010, 285:37159-37169.
95. Tu K., Yang W., Li C., Zheng X., Lu Z., Guo C., Yao Y., Liu Q. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol. Cancer 2014, 13:110.
96. Brodowska K., Al-Moujahed A., Marmalidou A., Meyer Zu Horste M., Cichy J., Miller J.W., Gragoudas E., Vavvas D.G. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp. Eye Res. 2014, 124:67-73.
97. Liu-Chittenden Y., Huang B., Shim J.S., Chen Q., Lee S.J., Anders R.A., Liu J.O., Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012, 26:1300-1305.
98. Yu F.X., Luo J., Mo J.S., Liu G., Kim Y.C., Meng Z., Zhao L., Peyman G., Ouyang H., Jiang W., Zhao J., Chen X., Zhang L., Wang C.Y., Bastian B.C., Zhang K., Guan K.L. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014, 25:822-830.
99. Feng X., Degese M.S., Iglesias-Bartolome R., Vaque J.P., Molinolo A.A., Rodrigues M., Zaidi M.R., Ksander B.R., Merlino G., Sodhi A., Chen Q., Gutkind J.S. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 2014, 25:831-845.
100. O'Hayre M., Degese M.S., Gutkind J.S. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr. Opin. Cell Biol. 2014, 27:126-135.
101. Clendening J.W., Pandyra A., Boutros P.C., El Ghamrasni S., Khosravi F., Trentin G.A., Martirosyan A., Hakem A., Hakem R., Jurisica I., Penn L.Z. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15051-15056.
102. Sorrentino G., Ruggeri N., Specchia V., Cordenonsi M., Mano M., Dupont S., Manfrin A., Ingallina E., Sommaggio R., Piazza S., Rosato A., Piccolo S., Del Sal G. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 2014, 16:357-366.
103. Wang Z., Wu Y., Wang H., Zhang Y., Mei L., Fang X., Zhang X., Zhang F., Chen H., Liu Y., Jiang Y., Sun S., Zheng Y., Li N., Huang L. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E89-E98.
104. Altwairgi A.K. Statins are potential anticancerous agents (Review). Oncol. Rep. 2015, 33:1019-1039.
105. Pobbati A.V., Chan S.W., Lee I., Song H., Hong W. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes. Structure 2012, 20:1135-1140.
106. Zhou Z., Hu T., Xu Z., Lin Z., Zhang Z., Feng T., Zhu L., Rong Y., Shen H., Luk J.M., Zhang X., Qin N. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. FASEB J. 2015, 29:724-732.
107. Johnson R., Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat. Rev. Drug Discov. 2014, 13:63-79.